이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Long-term Iron Absorption and Loss in Women

2026년 9월 28일 업데이트: Tippawan Pongcharoen, Mahidol University

Long-term Iron Absorption and Loss in Overweight/Obese Thai Middle-aged Women

Obese people typically have chronic low-grade inflammation. Based on short-term studies, this inflammation could affect the absorption, utilization, storage, and mobilization of iron, and individuals with inflammation might develop iron deficiency (ID) and anemia when inadequacy of iron intake is presented. The double burden of malnutrition is nowadays emerging as a major public health concern in many countries, including Thailand. Understanding the association of chronic inflammation among people with overweight or obesity (OW/OB) with long-term iron absorption and loss is important for developing appropriate policies and programs to promote iron balance and, consequently, optimal iron status and health outcomes. Since previous reports among Thai women showed a high prevalence of OW/OB and anemia, this study will be conducted to determine the long-term iron absorption and loss among OW/OB free-living women using the iron isotope dilution method.

연구 개요

상세 설명

  1. Research Objective To study iron absorption, loss, and long-term iron gain in overweight or obese middle-aged Thai women compared with normal-weight middle-aged Thai women.
  2. Research Methodology 2.1 Study design: This study is a longitudinal study comparing long-term iron absorption and loss between overweight or obese middle-aged Thai women and normal-weight middle-aged Thai women.

2.2 Study population: The study population consists of 64 women aged 40-50 years, divided into two groups: 32 overweight or obese women, and 32 normal-weight women.

2.3 Research Procedures 2.3.1 Before data collection: The research protocol is submitted for approval to the Central Institutional Review Board, Mahidol University. All data collectors will be trained prior to fieldwork. Upon receiving ethical approval, recruitment posters will be used to invite participants.

Screening process:

  1. Interested individuals meeting preliminary eligibility criteria will be informed about study details, sign informed consent, and schedule the first visit for screening and blood collection.

  2. Visit 1 (Screening):

    • Collect demographic and health history, measure weight, height, and body composition.
    • Collect 5 mL blood sample for Hb, SF, CRP, AGP, and hemoglobin typing.
    • Perform urine pregnancy test.
    • Administer one 400 mg albendazole tablet to prevent parasitic infection.

Iron isotope administration and follow-up:

2.3.2 Eligible participants will return within 1-2 weeks for the second visit.

Visit 2 (Month 0; M0):

Participants will consume a 15 mg ⁵⁷Fe isotope solution followed by 100 mg vitamin C drink, then fast for 3 hours.

A snack (plain yogurt and water) will be provided 1.5 hours after ingestion. A 24-hour dietary recall and semi-quantitative food frequency questionnaire (FFQ) will be conducted, with two additional 24-hour recalls by phone (2 weekdays and 1 weekend day).

Participants will then enter a 1-year equilibration period, recording illness and menstrual data monthly. The research team will monitor via LINE or email.

Visit 3 (Month 9; M9):

Collect fasting blood (5 mL) for Hb, glucose, HbA1c, and lipid profile; measure weight, BP, and conduct 24-hour recall (plus two by phone).

Visit 4 (After 1 year; WK0):

Collect fasting blood (10 mL) for Hb, SF, TfR, CRP, AGP, erythrocyte isotopic enrichment.

Measure weight, body composition, pregnancy test, and dietary recalls (3 days) and FFQ.

Visits 5-7 (WK8, WK16, WK24):

For eligible participants, repeat blood tests (7 mL) for Hb, SF, TfR, CRP, AGP, isotopic enrichment, anthropometry, pregnancy test, 3-day dietary recalls, and FFQ.

2.4 Research Instruments

  1. General information and medical history questionnaire, 24-hour dietary recall, and FFQ.

  2. Illness and menstrual record forms.

  3. Anthropometry and clinical measures:

    • Weight: InBody digital scale
    • Height: Harpenden stadiometer
    • Body composition: Bioelectrical Impedance Analyzer (BIA; InBody)
    • Blood pressure: Omron digital sphygmomanometer
  4. Laboratory analyses:

    • Hb: Complete Blood Count (CBC) using flow cytometry
    • SF, TfR, CRP, AGP: ELISA (SFa calculated from SF, CRP, AGP)
    • Hemoglobin typing: Capillary electrophoresis
    • Fasting glucose: Enzymatic method
    • HbA1c: Turbidimetric inhibition immunoassay
    • Lipids: Enzymatic colorimetric and homogeneous methods
    • Iron isotopes: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 2.5 Data Analysis Nutrient intake (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated using INMUCAL software.

Dietary patterns will be analyzed using Principal Component Analysis (PCA).

The average iron absorption (Fe_abs) over the study period will be calculated as:

Feabs=kabs×FetotalFe_{abs} = k_{abs} \times Fe_{total}Feabs=kabs×Fetotal where Fe_total is the total body iron at the midpoint estimated from the regression of Fe_total over time, and k_abs is the fractional iron absorption rate derived from the slope of the regression line of ln(⁵⁷Fe) vs. time.

Average iron loss (Fe_loss) is calculated similarly:

Feloss=kloss×FetotalFe_{loss} = k_{loss} \times Fe_{total}Feloss=kloss×Fetotal

Iron gain (Fe_gain) is calculated as:

Fegain=Feabs-FelossFe_{gain} = Fe_{abs} - Fe_{loss}Fegain=Feabs-Feloss Differences between groups in general characteristics, biochemical parameters, and iron absorption/loss slopes will be tested using Independent t-test or Mann-Whitney U-test, as appropriate.

A Linear Mixed-Effects Model will be used to analyze group differences in longitudinal changes of iron absorption, loss, and gain.

Statistical significance will be set at p < 0.05.

연구 유형

관찰

등록 (추정된)

64

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: Aree Prachansuwan, Ph.D.
  • 전화번호: +66890060602

연구 장소

      • Nakhon Pathom, 태국, 73170

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

40년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

여성

샘플링 방법

비확률 샘플

연구 인구

The study population will consist of 64 women aged 40-50 years, divided into two groups: 32 participants who are overweight or obese, and 32 participants with normal weight.

설명

Inclusion Criteria:

  • Normal weight group

    1. Aged 40-50 years
    2. Normal weight (BMI 18.5-22.9 kg/m²)
    3. Hb ≥12.0 g/dL and inflammation-adjusted SFa <50.0 µg/L
    4. CRP <5.0 mg/L
    5. Normal hemoglobin typing
    6. Plans to reside in the study area for >2 years
  • Overweight/obese group

    1. Aged 40-50 years
    2. Overweight or obese [Body Mass Index (BMI) ≥25.0 kg/m²] - the BMI cut-off follows the agreement of countries under the Coordinated Research Project (CRP) E43038 "Using the iron isotope dilution technique to assess the influence of inflammation on long-term iron absorption and loss," supported by the IAEA
    3. Hemoglobin (Hb) ≥12.0 g/dL and inflammation-adjusted serum ferritin (SFa) <50.0 µg/L
    4. C-reactive protein (CRP) between 5.0-25.0 mg/L
    5. Normal hemoglobin typing
    6. Plans to reside in the study area for >2 years

Exclusion Criteria:

  • Normal weight group

    1. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
    2. Having metabolic NCDs (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
    3. Pregnant, breastfeeding, or planning pregnancy during the study
    4. Chronic infectious disease (e.g., tuberculosis, AIDS)
    5. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
    6. Taking vitamin or mineral supplements during or within two weeks prior to the study
    7. Participating in a weight-loss program
    8. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
    9. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
    10. Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)
  • Overweight/obese group

    1. Obesity class II (BMI ≥35.0 kg/m²) with high health risk
    2. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
    3. Having metabolic noncommunicable diseases (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
    4. Pregnant, breastfeeding, or planning pregnancy during the study
    5. Chronic infectious disease (e.g., tuberculosis, AIDS)
    6. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
    7. Taking vitamin or mineral supplements during or within two weeks prior to the study
    8. Participating in a weight-loss program
    9. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
    10. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
    11. Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
Normal weight

BMI 18.5-22.9 kg/m2

Overweight or obesity

BMI 25-35 kg/m2

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Mean long-term iron absorption (Fe abs)
기간: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).

Calculated over the duration of the study as follows: Fe abs = k abs x Fe total Where Fe total is the total body iron at the midpoint, calculated from the linear regression of Fe total versus time across each measurement point; and k abs is the fraction of total body iron absorbed per unit of time (derived from the slope of the linear regression equation of ln 57 Fe versus time).

57 Fe isotope will be measured using Inductively Coupled Plasma Mass Spectrometry (ICP-MS).

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).
Mean long-term iron loss (Fe loss)
기간: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Calculated in the same manner as iron absorption: Fe loss = k loss x Fe total Where k loss is the fraction of total body iron lost per unit of time.

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Iron gain (Fe gain)
기간: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Calculated as net iron balance: Fe gain = Fe abs - Fe loss

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

2차 결과 측정

결과 측정
측정값 설명
기간
Weight (kg)
기간: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Weight will be measured in kg (to the nearest 0.1 kg) using an Inbody digital weighing scale.

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Height (cm)
기간: Visit 1 (Screening)

Height will be measured to the mearest 0.1 cm using a Harpenden stadiometer.

Visit 1 (Screening)
Body Mass Index (BMI, kg/m²)
기간: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

BMI will be calculatedn body weight in kilograms divided by height in meters squared.

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Body composition (fat mass)
기간: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)

Body composition (fat mass) will be measured using the Bioelectrical Impedance Analyzer (BIA; InBody).

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
Nutrient intakes
기간: Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Nutrient intakes (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated from 3-day 24-hr dietary recalls using INMUCAL software.

Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Dietary pattern
기간: Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)

Dietary patern from FFQ will be analyzed using the Principal Component Analysis (PCA)

Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
Hemoglobin (Hb, g/L)
기간: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Hb concentration will be assessed using flow cytometry

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Serum ferritin (SF, µg/L)
기간: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

SF will be measured using Enzyme-linked immunosorbent assay (ELISA)

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
serum transferrin receptor (sTfR µg/L)
기간: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

sTfR will be assessed using ELISA

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
c-reactive protein (CRP, mg/L)
기간: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

CRP will measured using ELISA

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
alpha-1 acid glycoprotein (AGP, g/L)
기간: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

AGP will be measured using ELISA

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Glycated hemoglobin (HbA1c, %)
기간: Visit 3 (Month 9)

HbA1c wil be measured by Turbidimetric inhibition immunoassay

Visit 3 (Month 9)
Lipid profile
기간: Visit 3 (Month 9)

Lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) will be measured using Enzymatic colorimetric and homogeneous methods.

Visit 3 (Month 9)
Blood pressure (BP, mmHg)
기간: Visit 3 (Month 9)

BP will be measured using Omron digital sphygmomanometer

Visit 3 (Month 9)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Veronica LOPEZ TEROS, Ph.D., Internation Atomic Energy Agency

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 5월 8일

기본 완료 (추정된)

2027년 12월 31일

연구 완료 (추정된)

2028년 8월 31일

연구 등록 날짜

최초 제출

2026년 8월 6일

QC 기준을 충족하는 최초 제출

2026년 9월 28일

처음 게시됨 (실제)

2026년 10월 2일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

IPD 계획 설명

There has been ongoing discussion regarding collaboration on data analysis and publication among countries that have conducted studies supported by the International Atomic Energy Agency (IAEA).

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다